Nashville-based Cumberland Pharmaceuticals Inc. announced today that the US FDA has granted Fast Track Designation for its oral ifetroban therapy targeting heart disease in Duchenne muscular dystrophy (DMD) patients.
Ifetroban is an oral small molecule thromboxane receptor antagonist designed to interrupt inflammatory and fibrotic processes in cardiac muscle. By blocking thromboxane A2 receptor signaling, the drug aims to potentially slow cardiac muscle deterioration and improve heart function in DMD patients.
DMD is a genetic disorder affecting approximately 1 in 3,500-5,000 male births. The disease is characterized by progressive muscle degeneration caused by mutations in the dystrophin gene, with cardiac complications emerging as the primary mortality risk. Currently, no therapies specifically address DMD-related heart disease, despite heart failure being the leading cause of death among patients.
Clinical context
The Fast Track Designation follows Cumberland’s Phase II FIGHT DMD trial, which demonstrated a 5.4% improvement in left ventricular ejection fraction over 12 months of treatment. This regulatory milestone enables more frequent FDA interactions and potentially expedited review processes.
Several companies are also developing therapies specifically aimed at the cardiac complications (DMD-associated cardiomyopathy), led by Capricor Therapeutics’ deramiocel (CAP-1002), allogeneic cardiosphere-derived cells (CDCs) which reported positive topline data from the Phase III HOPE-3 trial in December 2025 (including 91% slowing of cardiac progression via LVEF), and is on the way to an FDA approval filing. Other candidates Sardocor’s SRD-001, a gene therapy delivered directly to the heart, currently in Phase I study, and Solid Biosciences SGT-003, also a gene therapy currently in Phase I/II testing.